SEC Filing Analysis: Cardiff Lexington Corp (CDIX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Financial Officer received a restricted stock award of 25,000 shares as compensation, which vests in one year. This is a standard executive compensation event, not an open-market transaction.
• Market Impact: Neutral. Compensatory grants are common and generally do not cause significant market reactions unless they are unusually large.

Company Information

Field	Value
Company	Cardiff Lexington Corp
Ticker Symbol	CDIX
CIK	0000811222
Industry	Offices & Clinics of Doctors of Medicine

Insider Information

Field	Value
Name	Shafer Matthew T
CIK	0001684933
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

This filing reports two key events:

1. Restricted Stock Award (Grant)

Field	Value
Form Type	4
Transaction Date	2025-12-11
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	25,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	35,000
Ownership Type	Direct

2. Conversion of Preferred Stock

Field	Value
Form Type	4
Transaction Date	2025-11-19
Transaction Code	C (Conversion)
Security Type	Common Stock (Acquired) / Series I Preferred Stock (Disposed)
Shares Involved	Acquired 10,000 Common Stock by converting 5,000 Preferred Stock
Price Per Share	$0.00
Total Value	$0
Shares Owned After	10,000 (after this specific transaction)
Ownership Type	Direct

Financial Impact Assessment

Impact Evaluation

• Ownership Concentration: The CFO, Matthew T. Shafer, now directly owns 35,000 shares of common stock. Without data on total shares outstanding, the percentage of ownership cannot be determined.
• Dilution Impact: The grant of 25,000 shares comes from the company's 2024 Equity Incentive Plan. While this represents potential future dilution for existing shareholders, such plans are a standard method of executive compensation.
• Transaction Significance: The significance is rated as 'Low' because the transactions are a non-cash, compensatory grant and a conversion of previously-held securities. They do not represent a new investment decision or an open-market purchase, which would be a stronger indicator of insider sentiment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Compensatory stock grants are routine and expected for executive officers. They align management with shareholder interests but are not typically interpreted as a strong bullish or bearish signal in the same way an open-market buy or sell would be.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction is not an open-market trade and will not directly impact trading volume.
• Sentiment Indicator: Neutral. The filing confirms the CFO is being compensated with equity, which is standard practice.

Additional Context

Transaction Notes

• Grant Vesting: The 25,000 shares awarded on December 11, 2025, will vest in full one year later, on December 11, 2026, contingent upon the CFO's continued service.
• Conversion Details: The conversion on November 19, 2025, was an automatic conversion of all outstanding Series I Preferred Stock. The CFO had originally received these preferred shares as compensation in January 2024. Each preferred share converted into two shares of common stock.